Nanobiotix Shares Rise 5.46% in Session, Up 842% Over a Year
This Tuesday, Nanobiotix shows a significant increase of 5.46% to €27.80 in a generally well-oriented Parisian market. The French biotech company, specializing in nanotechnology applied to oncology, continues its spectacular trajectory with a performance of 842% over twelve months.
Current Session Performance
In today's session, the Nanobiotix stock is trading at €27.80, significantly above its 50-day moving average (€24.67) and even more so above its 200-day moving average (€16.28). This gap of more than 70% from the MM200 illustrates the magnitude of the bullish movement that has been underway for several months. Over three months, the stock has gained 53.59%, after having already increased nearly tenfold in a year. Regarding the Bollinger Bands, the price is in the upper part of the channel, at 69% between the lower bound (€24.35) and the upper bound (€29.38), without yet reaching the overbought threshold. The RSI at 51 confirms a neutral position, suggesting that today's rise is not yet accompanied by excessive tensions. The next resistance threshold identified is at €33.50, about 20% above the current price.
Market Context of Nanobiotix's Progress
Nanobiotix's progression occurs in a supportive market environment. The CAC 40 is up 0.79% in session at 8,300.93 points, while the SBF 120 advances by 0.83%. Across the Atlantic, the S&P 500 is up 1.02% in session and the Dow Jones appreciates by 0.63%. In the European health sector, performances are more mixed: Sanofi is up 1.17%, while UCB is down 0.18%. With an almost zero beta (-0.01), the Nanobiotix stock historically remains uncorrelated with major indices, suggesting that its recent trajectory is more related to company-specific factors than to the general trend. Monthly volatility remains high, at 23.46%, characteristic of a low-capitalization biotechnology stock. The support level to watch is at €25.25, approximately corresponding to the lower Bollinger Band.
